Table 3.

Selection of published phase 2 studies of newer agents in combination

ReferenceAgentRegimenNo. of patientsInclusion criteriaResponse, %Median PFS, moSafety
GradesAE, %
48 Pom 1-2.5 mg/d  69 1-3 previous lines 50 10.4 3-5 Neutropenia, 42 
Cy 50 mg every other day CR + VGPR, 23 Anemia, 9 
P 50 mg every other day Thrombocytopenia, 11 
49 Pom 4 mg/d, days 1-21 28-d cycles 70 2 or more previous lines 64.7 vs 38.9 9.5 vs 4.4 3-4 Neutropenia, 51 vs 31 
Cy 400 mg/d, days 1, 8, 15 vs 0 Len-refract Anemia, 24 vs 11 
Dex 40 mg/d, days 1-4, 15-18 Thrombocytopenia, 15 vs 6 
50 Pom 4 mg/m2, days 1-21 28-d cycles 47 1-4 previous lines 81 12% at 9 mo 3-4 Neutropenia, 62 
Bor 1.3 mg/m2, days, 8, 15, 22 Len-refract 38 CR + VGPR Lung infection, 13 
Dex  Dyspnea, 6 
  Syncope, 6 
51 Car 20/27 mg/m2, days 1-2, 8-9, 15-16 28-d cycles 32 Len-refract 50 7.2 3-5 63% AE 
Pom 4 mg/d, 21 d VGPR, 16 n = 3, Acute renal failure 
Dex 40 mg/d weekly n = 2, Toxic deaths 
52 Elo 10 or 20 mg/kg 28-d cycles 73 1-3 previous lines 92 vs 76  All grades Diarrhea, 66 
Len 25 mg/d VGPR, 47 vs 38 Muscle spasms, 62  
Dex  Fatigue, 56 
53 Pan 20 mg 3 × wk, weeks 1-2, 8 × 21-d cycles  55 2 or more previous lines 21.8 5.4 3-4 Diarrhea, 20 
Bor 1.3 mg/m2, days 1, 4, 8, 11 Bort-refract CR, 1.8 Fatigue, 20  
Dex 20 mg, days 1-2, 4-5, 8-9, 11-12 Thrombocytopenia, 64  
54 Da 16 mg/kg weekly × 8, every 2 wk × 8, monthly 28-d cycles 32 2-4 previous lines 81 72% at 18 mo 3-4 Neutropenia, 78 
Len 25 mg/d, days 1-2 and CR + VGPR, 37 Thrombocytopenia, 12.5 
Dex 40 mg/wk S-CR, 25 Anemia, 12.5 
56% IRR (3.6% grade 3) mostly first infusion 
ReferenceAgentRegimenNo. of patientsInclusion criteriaResponse, %Median PFS, moSafety
GradesAE, %
48 Pom 1-2.5 mg/d  69 1-3 previous lines 50 10.4 3-5 Neutropenia, 42 
Cy 50 mg every other day CR + VGPR, 23 Anemia, 9 
P 50 mg every other day Thrombocytopenia, 11 
49 Pom 4 mg/d, days 1-21 28-d cycles 70 2 or more previous lines 64.7 vs 38.9 9.5 vs 4.4 3-4 Neutropenia, 51 vs 31 
Cy 400 mg/d, days 1, 8, 15 vs 0 Len-refract Anemia, 24 vs 11 
Dex 40 mg/d, days 1-4, 15-18 Thrombocytopenia, 15 vs 6 
50 Pom 4 mg/m2, days 1-21 28-d cycles 47 1-4 previous lines 81 12% at 9 mo 3-4 Neutropenia, 62 
Bor 1.3 mg/m2, days, 8, 15, 22 Len-refract 38 CR + VGPR Lung infection, 13 
Dex  Dyspnea, 6 
  Syncope, 6 
51 Car 20/27 mg/m2, days 1-2, 8-9, 15-16 28-d cycles 32 Len-refract 50 7.2 3-5 63% AE 
Pom 4 mg/d, 21 d VGPR, 16 n = 3, Acute renal failure 
Dex 40 mg/d weekly n = 2, Toxic deaths 
52 Elo 10 or 20 mg/kg 28-d cycles 73 1-3 previous lines 92 vs 76  All grades Diarrhea, 66 
Len 25 mg/d VGPR, 47 vs 38 Muscle spasms, 62  
Dex  Fatigue, 56 
53 Pan 20 mg 3 × wk, weeks 1-2, 8 × 21-d cycles  55 2 or more previous lines 21.8 5.4 3-4 Diarrhea, 20 
Bor 1.3 mg/m2, days 1, 4, 8, 11 Bort-refract CR, 1.8 Fatigue, 20  
Dex 20 mg, days 1-2, 4-5, 8-9, 11-12 Thrombocytopenia, 64  
54 Da 16 mg/kg weekly × 8, every 2 wk × 8, monthly 28-d cycles 32 2-4 previous lines 81 72% at 18 mo 3-4 Neutropenia, 78 
Len 25 mg/d, days 1-2 and CR + VGPR, 37 Thrombocytopenia, 12.5 
Dex 40 mg/wk S-CR, 25 Anemia, 12.5 
56% IRR (3.6% grade 3) mostly first infusion 

Bor, bortezomib; Car, carfilzomib; Cy, cyclophosphamide; Da, daratumumab; Elo, elotuzumab; IRR, infusion-related reaction; P, prednisone; Pan, panobinostat; Pom, pomalidomide; s-CR, stringent complete response. Other abbreviations are explained in Tables 1 and 2.

View Large
Close Modal
This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal